<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838184</url>
  </required_header>
  <id_info>
    <org_study_id>PV_4805</org_study_id>
    <nct_id>NCT04838184</nct_id>
  </id_info>
  <brief_title>Short Implants in Edentulous Mandible</brief_title>
  <official_title>Prospective Clinical Study of Straumann Roxolid®/SLactive® Short Implants in Edentulous Mandible</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Straumann AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main aim of this study was to assess survival rates of short implants with a length of 4 mm&#xD;
      in the edentulous mandible after 1, 3, and 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is hypothesized that survival rates after 1, 3, and 5 years of Straumann Roxolid® /&#xD;
      SLActive® 4 mm short implants do not differ from values of Straumann SLActive implants with&#xD;
      more than 4 mm length in the same clinical situation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 19, 2015</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Survival of implants and suprastructure. Measure: survival rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implant stability</measure>
    <time_frame>3 months</time_frame>
    <description>Within-subject comparison of primary (at implant placement) and secondary (at implant exposure) stability of short versus regular length implants.&#xD;
Measure / device: Resonance Frequency Analysis (RFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success</measure>
    <time_frame>5 years</time_frame>
    <description>Success of implants and suprastructure. Measure: success rates&#xD;
Biological success:&#xD;
No detectable clinical mobility (hand testing)&#xD;
No radiolucency surrounding the total surface of the implant&#xD;
No persistent pain refractory to medical therapy&#xD;
No recurrent peri-implant infection&#xD;
Peri-implant infection: peri-implant Probing Depth (PD), Plaque Index (Pl), and Bleeding on Probing (BoP)&#xD;
Bone loss: standardized intra-oral radiography with long-cone parallel technique&#xD;
Technical success:&#xD;
No screw loosening&#xD;
No fracture of metal base&#xD;
No fracture of veneering material</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral health-related quality of life</measure>
    <time_frame>5 years</time_frame>
    <description>Oral health-related quality of life (OHRQoL). Measure: questionnaire&#xD;
- 49-item Oral Health Impact Profile (OHIP) with a 5-point ordinal rating scale (possible range of summary scores: 0-196 with higher scores indicating more impairment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>5 years</time_frame>
    <description>Patient satisfaction. Measure: questionnaire&#xD;
- Visual analogue scales (VAS) on ease of cleaning, speech, comfort, esthetic, stability, chewing ability, masticatory function, and oral health (possible range of scores: 0-10 for each item with higher scores indicating more satisfaction)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Tooth Loss</condition>
  <condition>Edentulous Jaw</condition>
  <arm_group>
    <arm_group_label>Dental patients</arm_group_label>
    <description>Patients with an edentulous mandible who are demanding and receiving an implant-supported fixed dental prosthesis in the mandible</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dental Implants (Straumann Roxolid® / SLActive®)</intervention_name>
    <description>In this study the 4 mm implants will be inserted in the area surrounding 36/46. The implant diameters will be defined based on the patient's situation.&#xD;
In the interforaminal region, two implants of conventional length with a minimum of 10 mm will be inserted. The implant diameter and the length will be defined based on the patient's situation.</description>
    <arm_group_label>Dental patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Dental patients of university-based prosthodontic department (primary, secondary, and&#xD;
        tertiary care clinic)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General criteria:&#xD;
&#xD;
          -  Age: 18 to 70&#xD;
&#xD;
          -  Edentulous mandible with reduced bone level in the posterior region (&gt; 5 mm and &lt; 8 mm&#xD;
             above nerve conduit)&#xD;
&#xD;
          -  Physical and mental condition that allow surgery and a 5-year follow-up period to be&#xD;
             carried out without foreseeable problems&#xD;
&#xD;
          -  Obtained informed consent from the patient&#xD;
&#xD;
        Specific criteria:&#xD;
&#xD;
          -  Limited vertical space for implant placement, where conventional implants with lengths&#xD;
             of more than 4 mm cannot be used&#xD;
&#xD;
          -  Tooth loss or extraction at least 8 weeks before implant surgery&#xD;
&#xD;
          -  Healthy implantation site&#xD;
&#xD;
          -  Favorable and stable occlusal relationship&#xD;
&#xD;
          -  Complete denture in the mandible. If no denture available, an interims prosthesis will&#xD;
             be fitted&#xD;
&#xD;
          -  Natural full dentition or sufficient complete or partial dentures in the maxilla&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General criteria:&#xD;
&#xD;
          -  Any conditions or circumstances which would interfere with the requirements for oral&#xD;
             surgery&#xD;
&#xD;
          -  Allergy to any metallic implant component&#xD;
&#xD;
          -  Acute, untreated periodontitis&#xD;
&#xD;
          -  Previous oro-maxillo-facial radiotherapy&#xD;
&#xD;
          -  Any disorders in the planned implant area such as previous tumors or chronic bone&#xD;
             disease (e.g., rheumatoid disease)&#xD;
&#xD;
          -  Any ongoing application of interfering medication (steroid therapy, bisphosphonate,&#xD;
             etc.)&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Heavy smoking (&gt;10 cigarettes/day)&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Severe bruxism or other destructive oral habits&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
        Specific criteria:&#xD;
&#xD;
          -  Need for a major bone regeneration technique&#xD;
&#xD;
          -  Infections in adjacent tissue of the planned implantation site.&#xD;
&#xD;
          -  Bleeding on probing (BOP) and plaque index (PI) higher 25%&#xD;
&#xD;
          -  Insufficient bone volume in the posterior region for placing a Straumann Roxolid® /&#xD;
             SLActive® 4mm short implant and in the interforaminal region for placing a Straumann&#xD;
             Roxolid® / SLActive® implant with a minimum length of 10 mm determined by radiographic&#xD;
             analysis (OPG)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
    <mesh_term>Mouth, Edentulous</mesh_term>
    <mesh_term>Tooth Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

